Recurrence and Malignant Transformation After Borderline Ovarian Tumors: A Systematic Review and Meta-analysis.
Borderline ovarian tumours (BOTs) frequently affect women of reproductive age. Fertility-sparing surgery (FSS) is commonly offered, but recurrence risk varies by surgical approach and histological subtype, while malignant transformation remains incompletely defined. This systematic review and meta-analysis aimed to quantify recurrence and malignant transformation risks following different surgical strategies for BOTs.
A prospectively registered protocol (PROSPERO: CRD420251172155) was followed. Studies of adult women with histologically confirmed BOTs undergoing FSS - unilateral or bilateral cystectomy, unilateral salpingo-oophorectomy (USO), or USO with contralateral cystectomy - or radical surgical staging (pelvic clearance) were included. Random-effects meta-analyses generated pooled risk estimates with 95% confidence intervals (CIs); heterogeneity was assessed using I2. Methodological quality was evaluated using MINORS.
Forty-one studies including 5,364 women were analyzed, with follow-up ranging from 7 months to 15 years. Recurrence following FSS was highest after cystectomy-based procedures: 0.31 (95%CI=0.15-0.47; I2=97.24%) after unilateral cystectomy and 0.41 (0.26-0.57; I2=80.59%) after bilateral cystectomy. Lower recurrence was observed after USO (0.13; 0.10-0.16; I2=81.55%) and USO with contralateral cystectomy (0.31; 0.17-0.45; I2=91.40%). Radical surgery was associated with the lowest recurrence risk (0.03; 0.02-0.04; I2=26.42%). In serous BOTs, recurrence after cystectomy was 0.29 (0.23-0.56) and after USO 0.15 (0.09-0.24). In mucinous BOTs, corresponding estimates were 0.26 (0.14-0.38) and 0.08 (0.02-0.13). Overall malignant transformation occurred in 1% of women (0.01; 0.01-0.02) but increased substantially following recurrence (0.22).
Cystectomy-based FSS is associated with significantly higher recurrence than oophorectomy-based approaches or radical surgery. Although malignant transformation is rare overall, its marked increase following recurrence highlights the need for histology-informed counselling and long-term, risk-adapted surveillance.
A prospectively registered protocol (PROSPERO: CRD420251172155) was followed. Studies of adult women with histologically confirmed BOTs undergoing FSS - unilateral or bilateral cystectomy, unilateral salpingo-oophorectomy (USO), or USO with contralateral cystectomy - or radical surgical staging (pelvic clearance) were included. Random-effects meta-analyses generated pooled risk estimates with 95% confidence intervals (CIs); heterogeneity was assessed using I2. Methodological quality was evaluated using MINORS.
Forty-one studies including 5,364 women were analyzed, with follow-up ranging from 7 months to 15 years. Recurrence following FSS was highest after cystectomy-based procedures: 0.31 (95%CI=0.15-0.47; I2=97.24%) after unilateral cystectomy and 0.41 (0.26-0.57; I2=80.59%) after bilateral cystectomy. Lower recurrence was observed after USO (0.13; 0.10-0.16; I2=81.55%) and USO with contralateral cystectomy (0.31; 0.17-0.45; I2=91.40%). Radical surgery was associated with the lowest recurrence risk (0.03; 0.02-0.04; I2=26.42%). In serous BOTs, recurrence after cystectomy was 0.29 (0.23-0.56) and after USO 0.15 (0.09-0.24). In mucinous BOTs, corresponding estimates were 0.26 (0.14-0.38) and 0.08 (0.02-0.13). Overall malignant transformation occurred in 1% of women (0.01; 0.01-0.02) but increased substantially following recurrence (0.22).
Cystectomy-based FSS is associated with significantly higher recurrence than oophorectomy-based approaches or radical surgery. Although malignant transformation is rare overall, its marked increase following recurrence highlights the need for histology-informed counselling and long-term, risk-adapted surveillance.
Authors
Taniskidi Taniskidi, Giannas Giannas, Lekka Lekka, Taniskidi Taniskidi, Lecoyte Lecoyte, Brincat Brincat, Dilley Dilley, Jeyarajah Jeyarajah, Lawrence Lawrence, Brockbank Brockbank, Phadnis Phadnis, Manchanda Manchanda, Sideris Sideris
View on Pubmed